Merck & Co., Inc. (MRK) Stock
MRK Key Statistics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
CEO: Robert Davis. Company website
MRK — Frequently Asked Questions
What is the MRK stock price today?
Merck & Co., Inc. (MRK) trades at $147.19, down 0.58% on the day, as of Nov 12, 2026 09:20 UTC.
What is Merck & Co., Inc.'s market cap?
Merck & Co., Inc. has a market capitalisation of $363.14B, calculated from the live MRK share price and shares outstanding.
What is the P/E ratio of MRK?
MRK trades at a trailing P/E of 151.45, from earnings per share of $0.97 over the last twelve months.
How much revenue does Merck & Co., Inc. make?
Merck & Co., Inc. generated revenue of $67.38B over the trailing twelve months, which puts the stock at 5.39 times sales.
Does MRK pay a dividend?
Yes. Merck & Co., Inc. pays a dividend yielding 3.02% on the current share price.
What is the 52-week range for MRK?
MRK has traded between $85.24 and $156.92 over the past 52 weeks, and the last price is 6.2% below that high.
Is Merck & Co., Inc. profitable?
Yes. Merck & Co., Inc. keeps 3.64% of revenue as net income over the trailing twelve months.
What is the analyst price target for MRK?
Wall Street analysts rate MRK Buy, with an average price target of $160.47, 9.0% above the current price.
What sector is Merck & Co., Inc. in?
Merck & Co., Inc. is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in US.
Who is the CEO of Merck & Co., Inc.?
Robert Davis is the chief executive of Merck & Co., Inc., which employs 74,000 people.
Where can I track MRK in real time?
QFI Terminal shows MRK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See MRK live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open MRK in Terminal See plans